...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cost Effectiveness Resource Allocation >Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries
【24h】

Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries

机译：坚持治疗与精神分裂症患者健康教育的成本效益：在四个欧洲国家的随机对照试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Non-adherence to anti-psychotics is common, expensive and affects recovery. We therefore examine the cost-effectiveness of adherence therapy for people with schizophrenia by multi-centre randomised trial in Amsterdam, London, Leipzig and Verona. Methods Participants received 8 sessions of adherence therapy or health education. We measured lost productivity and use of health/social care, criminal justice system and informal care at baseline and one year to estimate and compare mean total costs from health/social care and societal perspectives. Outcomes were the Short Form 36 (SF-36) mental component score (MCS) and quality-adjusted life years (QALYs) gained (SF-36 and EuroQoL 5 dimension (EQ5D)). Cost-effectiveness was examined for all cost and outcome combinations using cost-effectiveness acceptability curves (CEACs). Results 409 participants were recruited. There were no cost or outcome differences between adherence therapy and health education. The probability of adherence therapy being cost-effective compared to health education was between 0.3 and 0.6 for the six cost-outcome combinations at the willingness to pay thresholds we examined. Conclusions Adherence therapy appears equivalent to health education. It is unclear whether it would have performed differently against a treatment as usual control, whether such an intervention can impact on quality of life in the short-term, or whether it is likely to be cost-effective in some sites but not others. Trial registration Trial registration: Current Controlled Trials ISRCTN01816159
机译：背景技术不坚持使用抗精神病药是普遍的，昂贵的并且会影响康复。因此，我们通过在阿姆斯特丹，伦敦，莱比锡和维罗纳进行的多中心随机试验研究了对精神分裂症患者进行依从治疗的成本效益。方法参加者接受了8次坚持治疗或健康教育。我们在基线和一年期间测量了生产力的损失以及对医疗/社会护理，刑事司法系统和非正式护理的使用，以估计和比较从医疗/社会护理和社会角度来看的平均总成本。结果是获得了简短的36式（SF-36）心理成分评分（MCS）和获得的质量调整生命年（QALYs）（SF-36和EuroQoL 5维度（EQ5D））。使用成本效益可接受性曲线（CEAC）检查了所有成本和结果组合的成本效益。结果招募了409名参与者。坚持治疗和健康教育之间没有成本或结果差异。在我们研究的支付意愿阈值下，对于六个成本-收益组合，坚持治疗相对于健康教育而言具有成本效益的可能性在0.3到0.6之间。结论坚持治疗似乎等同于健康教育。尚不清楚它是否会与通常的对照治疗有所不同，这种干预是否会在短期内影响生活质量，或者在某些场所是否可能具有成本效益，而在其他场所则没有。试用注册试用注册：现行对照试验ISRCTN01816159

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号